Roivant Sciences Financials
Roivant Sciences (ROIV) reported $7.5M in revenue over the twelve months to Jun 30, 2026, down 67.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development spending dominates Roivant’s model, with cash resources funding research far more than current revenue can support.
In FY2026,$681.8M of R&D stood against just$8.3M of revenue, defining a development-stage model rather than a revenue-funded operating business. Operating cash outflow was$750.3M , nearly matching free cash flow of-$758.6M ; the small gap indicates that reported cash needs closely track core operations and reinvestment.
Cash fell from
FY2026 R&D was
Financial Health Signals
Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Roivant Sciences's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Roivant Sciences scores 36.75, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($25.1B) relative to total liabilities ($416.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Roivant Sciences passes 0 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Roivant Sciences reported a net loss of $299.8M while operations used $750.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Roivant Sciences generated $8.3M in revenue in fiscal year 2026. This represents a decrease of 71.6% from the prior year.
Roivant Sciences's EBITDA was -$511.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 48.3% from the prior year.
Roivant Sciences reported -$299.8M in net income in fiscal year 2026. This represents a decrease of 74.3% from the prior year.
Roivant Sciences earned -$0.54 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 125.0% from the prior year.
Cash & Balance Sheet
Roivant Sciences recorded an outflow of $758.6M in free cash flow in fiscal year 2026, representing a cash shortfall after capex. This represents an increase of 10.1% from the prior year.
Roivant Sciences held $1.4B in cash as of fiscal year 2026; long-term debt is not reported for that period.
Not reported for fiscal year 2026.
Margins & Returns
Roivant Sciences's ROE was -6.6% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 2.9 percentage points from the prior year.
Not reported for fiscal year 2026.
Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Roivant Sciences invested $681.8M in research and development in fiscal year 2026. This represents an increase of 23.9% from the prior year.
Roivant Sciences invested $8.2M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 78.5% from the prior year.
Not reported for fiscal year 2026.
ROIV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M-42.8% | $2.5M+26.1% | $2.0M+27.2% | $1.6M-27.6% | $2.2M-71.3% | $7.6M-16.1% | $9.0M+101.5% | $4.5M |
| R&D Expenses | $202.0M+1.5% | $198.9M+20.3% | $165.4M+0.5% | $164.6M+7.6% | $152.9M+5.3% | $145.2M+2.6% | $141.6M-1.0% | $143.1M |
| SG&A Expenses | $165.5M+4.6% | $158.3M-9.6% | $175.1M+22.3% | $143.1M+6.8% | $134.0M+36.1% | $98.5M-30.4% | $141.5M-30.2% | $202.9M |
| Operating Income | -$366.0M-188.1% | $415.2M+222.4% | -$339.2M-10.7% | -$306.2M-7.5% | -$284.9M0.0% | -$285.0M-3.9% | -$274.4M+19.7% | -$341.7M |
| Income Tax | -$4.0M-104.0% | $98.4M+321.5% | $23.3M+233.6% | $7.0M+50.5% | $4.6M-90.6% | $49.3M+292.9% | -$25.6M-305.2% | $12.5M |
| Net Income | -$189.8M-162.7% | $303.0M+214.0% | -$265.9M-134.2% | -$113.5M+49.2% | -$223.4M-8.2% | -$206.5M-221.9% | $169.4M+173.6% | -$230.2M |
| EPS (Diluted) | -$0.26-176.5% | $0.34+189.5% | -$0.38-123.5% | -$0.17+48.5% | -$0.33-13.8% | -$0.29-226.1% | $0.23+174.2% | -$0.31 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
ROIV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.3B-7.0% | $5.7B+9.2% | $5.2B+3.2% | $5.1B+0.6% | $5.0B-7.4% | $5.4B-6.1% | $5.8B-6.7% | $6.2B |
| Current Assets | $4.7B-8.2% | $5.2B+10.9% | $4.7B+3.3% | $4.5B-2.3% | $4.6B-7.7% | $5.0B-6.8% | $5.4B-7.5% | $5.8B |
| Cash & Equivalents | $1.2B-12.0% | $1.4B-4.0% | $1.5B+19.5% | $1.2B-0.1% | $1.2B-54.4% | $2.7B+36.4% | $2.0B+1.6% | $2.0B |
| Total Liabilities | $384.6M-7.6% | $416.3M+65.8% | $251.1M-2.3% | $257.1M+18.7% | $216.7M-13.2% | $249.7M-2.6% | $256.4M-59.0% | $626.0M |
| Current Liabilities | $283.6M+0.8% | $281.2M+85.1% | $152.0M+13.5% | $133.9M+17.6% | $113.9M-23.8% | $149.4M+5.6% | $141.5M-74.6% | $556.2M |
| Total Equity | $4.2B-6.5% | $4.5B+6.0% | $4.3B-2.1% | $4.4B+0.4% | $4.3B-7.3% | $4.7B-9.7% | $5.2B+0.7% | $5.2B |
| Retained Earnings | -$900.4M-79.4% | -$501.8M+27.8% | -$695.0M-62.0% | -$429.1M-36.0% | -$315.6M-371.9% | $116.1M-74.8% | $460.4M+16.4% | $395.6M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ROIV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$270.5M-65.1% | -$163.8M+16.6% | -$196.5M-5.8% | -$185.7M+9.2% | -$204.4M-18.4% | -$172.6M+16.7% | -$207.3M+22.3% | -$266.8M |
| Capital Expenditures | $419K-66.8% | $1.3M-74.4% | -$4.9M-37.1% | $7.8M+94.5% | $4.0M+397.5% | $811K-55.6% | $1.8M+83.4% | $996K |
| Free Cash Flow | -$270.9M-64.1% | -$165.1M+18.0% | -$201.4M-4.1% | -$193.5M+7.2% | -$208.4M-20.2% | -$173.4M+17.1% | -$209.1M+21.9% | -$267.8M |
| Investing Cash Flow | $281.3M+62.1% | $173.5M+58.5% | $109.5M-9.1% | $120.4M+111.1% | -$1.1B-201.1% | $1.1B+136.6% | $454.1M+113.8% | -$3.3B |
| Financing Cash Flow | -$181.5M-163.9% | -$68.8M-121.0% | $328.2M+424.4% | $62.6M+133.3% | -$187.8M-6.0% | -$177.2M+35.1% | -$273.0M-150.2% | -$109.1M |
| Share Buybacks | $206.7M | N/A | $0 | $0-100.0% | $208.3M-29.5% | $295.4M+21.4% | $243.3M+129.5% | $106.1M |
Not reported in any period shown, so not listed: Dividends Paid.
ROIV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -25380.9% | 16477.8% | -16966.1% | -19492.9% | -13130.0% | -3764.4% | -3042.6% | -7636.0% |
| Net Margin | -13164.8% | 12023.6% | -13301.2% | -7225.9% | -10292.9% | -2727.5% | 1878.3% | -5143.8% |
| Return on Equity | -4.5%-11.2pp | 6.7%+12.9pp | -6.2%-3.6pp | -2.6%+2.5pp | -5.1%-0.7pp | -4.4%-7.7pp | 3.3%+7.7pp | -4.5% |
| Return on Assets | -3.6%-8.9pp | 5.3%+10.4pp | -5.1%-2.9pp | -2.2%+2.2pp | -4.4%-0.6pp | -3.8%-6.7pp | 2.9%+6.6pp | -3.7% |
| Current Ratio | 16.72-1.7x | 18.37-12.3x | 30.66-3.0x | 33.70-6.8x | 40.54+7.1x | 33.47-4.4x | 37.91+27.5x | 10.43 |
| Debt-to-Equity | 0.090.0x | 0.090.0x | 0.060.0x | 0.060.0x | 0.050.0x | 0.050.0x | 0.05-0.1x | 0.12 |
| FCF Margin | -18788.0% | -6550.7% | -10076.0% | -12317.8% | -9604.5% | -2290.3% | -2318.4% | -5984.4% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Roivant Sciences Ranks
Frequently Asked Questions
What is Roivant Sciences's annual revenue?
Roivant Sciences (ROIV) reported $8.3M in total revenue for fiscal year 2026. This represents a -71.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Roivant Sciences's revenue growing?
Roivant Sciences (ROIV) revenue declined by 71.6% year-over-year, from $29.1M to $8.3M in fiscal year 2026.
Is Roivant Sciences profitable?
No, Roivant Sciences (ROIV) reported a net income of -$299.8M in fiscal year 2026.
What is Roivant Sciences's EBITDA?
Roivant Sciences (ROIV) had EBITDA of -$511.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Roivant Sciences's return on equity (ROE)?
Roivant Sciences (ROIV) has a return on equity of -6.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Roivant Sciences's free cash flow?
Roivant Sciences (ROIV) recorded an outflow of $758.6M in free cash flow during fiscal year 2026. This represents a 10.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Roivant Sciences's operating cash flow?
Roivant Sciences (ROIV) recorded an outflow of $750.3M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Roivant Sciences's total assets?
Roivant Sciences (ROIV) had $5.7B in total assets as of fiscal year 2026, including both current and long-term assets.
What are Roivant Sciences's capital expenditures?
Roivant Sciences (ROIV) invested $8.2M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Roivant Sciences spend on research and development?
Roivant Sciences (ROIV) invested $681.8M in research and development during fiscal year 2026.
What is Roivant Sciences's current ratio?
Roivant Sciences (ROIV) had a current ratio of 18.37 as of fiscal year 2026, which is generally considered healthy.
What is Roivant Sciences's debt-to-equity ratio?
Roivant Sciences (ROIV) had a debt-to-equity ratio of 0.09 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Roivant Sciences's return on assets (ROA)?
Roivant Sciences (ROIV) had a return on assets of -5.3% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
How does Roivant Sciences's liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Roivant Sciences (ROIV) held $4.3B in cash, cash equivalents and investments, and reported an operating cash outflow of $750.3M over that year. Dividing the one by the other, the reported balance equals about 69 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Roivant Sciences's Altman Z-Score?
Roivant Sciences (ROIV) has an Altman Z-Score of 36.75, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Roivant Sciences's Piotroski F-Score?
Roivant Sciences (ROIV) has a Piotroski F-Score of 0 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Roivant Sciences's earnings high quality?
Roivant Sciences (ROIV) reported a net loss of $299.8M while operations used $750.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Roivant Sciences?
Roivant Sciences (ROIV) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.